REGENXBIO Inc. (NASDAQ: RGNX) recently faced a significant negative revision in both revenue and earnings per share (EPS) forecasts by analysts. This downgrade has led to a notable shift in sentiment towards the company, with the consensus now projecting revenues of US$255 million in 2025, reflecting a substantial 64% increase compared to the past year. On the EPS front, the loss per share is expected to narrow by 79% to US$0.73, which contrasts sharply with the previous forecast of revenues reaching US$336 million and losses of US$0.17 per share for the same period. The revised estimates indicate a more pessimistic outlook for the company’s financial performance in the near term.
The consensus price target for REGENXBIO dropped by 5.3% to US$29.75 post the downgrade, signaling concerns among analysts regarding the company’s future prospects following the weaker revenue and earnings outlook. When considering these estimates in a broader context, it becomes apparent that REGENXBIO is anticipated to experience a significant acceleration in growth, with revenue forecasted to grow by 169% annually until the end of 2025. This growth trajectory surpasses the company’s historical decline of 12% per year over the past five years, positioning it favorably against its industry peers whose revenue is predicted to increase by 19% per year.
Key Takeaways:
– REGENXBIO Inc. witnessed a substantial negative revision in revenue and EPS forecasts by analysts, indicating a shift in sentiment towards the company’s performance.
– The revised estimates project a significant growth in revenues and a reduction in losses per share for the company by 2025, albeit lower than the previous forecasts.
– The consensus price target for REGENXBIO decreased post the downgrade, highlighting concerns among analysts about the company’s future earnings potential.
– Despite the short-term challenges, the company is expected to outperform its competitors in terms of revenue growth, indicating a positive long-term trajectory in value creation for shareholders.
Read more on finance.yahoo.com